Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
Period:
Draw Mode:
| Volume | 6,145 |
|
|||||
| News | - | ||||||
| Day High | 17.65 | Low High |
|||||
| Day Low | 16.852 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Lexeo Therapeutics Inc | LXEO | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| -0.21 | -1.20% | 17.24 | 09:47:07 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 17.21 | 16.852 | 17.65 | 17.45 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 46 | 6,145 | $ 17.16 | $ 105,434 | - | 9.00 - 22.33 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 09:49:44 | 9 | $ 17.20 | USD |
Lexeo Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 459.77M | 26.67M | - | 0 | -66.39M | -2.49 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Lexeo Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical LXEO Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 16.01 | 17.985 | 15.32 | 17.12 | 245,502 | 1.23 | 7.68% |
| 1 Month | 14.48 | 17.985 | 12.98 | 15.67 | 155,696 | 2.76 | 19.06% |
| 3 Months | 15.91 | 17.985 | 11.57 | 14.51 | 144,266 | 1.33 | 8.36% |
| 6 Months | 13.96 | 22.33 | 10.00 | 14.70 | 118,500 | 3.28 | 23.50% |
| 1 Year | 9.50 | 22.33 | 9.00 | 14.05 | 126,388 | 7.74 | 81.47% |
| 3 Years | 9.50 | 22.33 | 9.00 | 14.05 | 126,388 | 7.74 | 81.47% |
| 5 Years | 9.50 | 22.33 | 9.00 | 14.05 | 126,388 | 7.74 | 81.47% |
Lexeo Therapeutics Description
| Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated; and LX2022, a gene therapy candidate for the treatment of HCM caused by TNNI3 mutations. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York. |
